Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Oncology|January 17, 2024
Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical OncologistsUdit Nindra, Victoria Bray, Deme Karikios, et al.
Internal Medicine Journal|July 26, 2017
Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health DistrictPei N Ding, Tara L Roberts, Wei Chua, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 21, 2016
Prognostic utility of (18)F-FDG PET-CT performed prior to and during primary radiotherapy for nasopharyngeal carcinoma: Index node is a useful prognostic imaging biomarker sitePeter Lin, Myo Min, Mark Lee, et al.
Thoracic Cancer|August 16, 2019
Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinibPei N Ding, Therese Becker, Victoria Bray, et al.
Plos One|January 22, 2021
Treatment burden experienced by patients with lung cancerNicole El-Turk, Michael S H Chou, Natasha C H Ting, et al.
Journal of Medical Imaging and Radiation Oncology|February 13, 2016
18F-FDG PET-CT performed before and during radiation therapy of head and neck squamous cell carcinoma: Are they independent or complementary to each other?Myo Min, Peter Lin, Mark Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2016
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung CancerPei Ni Ding, Sarah J Lord, Val Gebski, et al.
Asia-Pacific Journal of Clinical Oncology|March 1, 2023
Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumabUdit Nindra, Adel Shahnam, Samuel Stevens, et al.
Thoracic Cancer|September 16, 2022
Elevated neutrophil-to-lymphocyte ratio (NLR) is associated with poorer progression-free survival in unresectable stage III NSCLC treated with consolidation durvalumabUdit Nindra, Adel Shahnam, Samuel Stevens, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 18, 2015
Prognostic role of metabolic parameters of (18)F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinomaMyo Min, Peter Lin, Mark T Lee, et al.
Pageof 4